US Stocks Movement: Cullinan surges on October 6 due to new drug application, lung cancer drug, and T-cell therapy

Cullinan October 6th: Analysis of the Surge

Keywords: new drug application, lung cancer drug, T cell therapy

1. On October 1st, the company initiated a new drug application submission to the U.S. Food and Drug Administration for zipalertinib in combination with platinum-based chemotherapy to treat EGFR exon 20 insertion mutation non-small cell lung cancer, and the project was included in the Real-Time Oncology Review program. The application is expected to be completed by the end of 2026, based on the REZILIENT3 Phase 3 trial meeting its primary endpoint.

2. On September 24th, the company announced its clinical data plans for the fourth quarter: in November, it will disclose multiple-dose data for velinotamig in systemic lupus erythematosus; in December, it will disclose data for CLN-978 in systemic lupus erythematosus, rheumatoid arthritis, and Sjögren's syndrome, as well as updated data from the CLN-049 Phase 1 dose escalation study.

3. On August 6th, the company disclosed that its main focus is developing potential first-in-class or best-in-class disease-modifying T cell engagers for autoimmune diseases and cancer. Its clinical-stage pipeline covers the fields of immunology and oncology.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)